203 related articles for article (PubMed ID: 9568482)
21. Diagnosis and reversal of multidrug resistance in paediatric cancers.
Chan HS; Grogan TM; DeBoer G; Haddad G; Gallie BL; Ling V
Eur J Cancer; 1996 Jun; 32A(6):1051-61. PubMed ID: 8763347
[No Abstract] [Full Text] [Related]
22. Saturation reversal of the multidrug pump using many reversers in low-dose combinations.
Lyubimov E; Lan LB; Pashinsky I; Ayesh S; Stein WD
Anticancer Drugs; 1995 Dec; 6(6):727-35. PubMed ID: 8845484
[TBL] [Abstract][Full Text] [Related]
23. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells.
Aoki S; Chen ZS; Higasiyama K; Setiawan A; Akiyama S; Kobayashi M
Jpn J Cancer Res; 2001 Aug; 92(8):886-95. PubMed ID: 11509122
[TBL] [Abstract][Full Text] [Related]
24. The P-glycoprotein multidrug transporter: interactions with membrane lipids, and their modulation of activity.
Sharom FJ
Biochem Soc Trans; 1997 Aug; 25(3):1088-96. PubMed ID: 9388605
[No Abstract] [Full Text] [Related]
25. Therapeutic approach to drug resistant tumors.
Naito M; Tsuruo T
Ther Drug Monit; 1998 Oct; 20(5):577-80. PubMed ID: 9780138
[TBL] [Abstract][Full Text] [Related]
26. Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
Callaghan R; Higgins CF
Br J Cancer; 1995 Feb; 71(2):294-9. PubMed ID: 7841043
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein: its role in drug resistance.
Ling V
Am J Med; 1995 Dec; 99(6A):31S-34S. PubMed ID: 8585532
[No Abstract] [Full Text] [Related]
28. Drug resistance in lung cancer.
Nishio K; Nakamura T; Koh Y; Suzuki T; Fukumoto H; Saijo N
Curr Opin Oncol; 1999 Mar; 11(2):109-15. PubMed ID: 10188075
[TBL] [Abstract][Full Text] [Related]
29. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate.
Eytan GD; Regev R; Oren G; Hurwitz CD; Assaraf YG
Eur J Biochem; 1997 Aug; 248(1):104-12. PubMed ID: 9310367
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein multidrug resistance and cancer.
Bosch I; Croop J
Biochim Biophys Acta; 1996 Oct; 1288(2):F37-54. PubMed ID: 8876632
[No Abstract] [Full Text] [Related]
31. Multidrug resistance proteins and other drug transport-related resistance to natural product agents.
Broxterman HJ; Giaccone G; Lankelma J
Curr Opin Oncol; 1995 Nov; 7(6):532-40. PubMed ID: 8547402
[TBL] [Abstract][Full Text] [Related]
32. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein.
Tanaka K; Hirai M; Tanigawara Y; Yasuhara M; Hori R; Ueda K; Inui K
Pharm Res; 1996 Jul; 13(7):1073-7. PubMed ID: 8842048
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance: overcoming the good, the bad, and the ugly.
Rund D
Leuk Lymphoma; 2010 Oct; 51(10):1771-2. PubMed ID: 20846098
[No Abstract] [Full Text] [Related]
34. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes.
Vergote J; Moretti JL; de Vries EG; Garnier-Suillerot A
Eur J Biochem; 1998 Feb; 252(1):140-6. PubMed ID: 9523723
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
36. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.
Sharom FJ; Yu X; Lu P; Liu R; Chu JW; Szabó K; Müller M; Hose CD; Monks A; Váradi A; Seprôdi J; Sarkadi B
Biochem Pharmacol; 1999 Aug; 58(4):571-86. PubMed ID: 10413294
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation.
Shustik C; Dalton W; Gros P
Mol Aspects Med; 1995; 16(1):1-78. PubMed ID: 7783568
[No Abstract] [Full Text] [Related]
38. Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter.
Prokopenko O; Mirochnitchenko O
Am J Physiol Cell Physiol; 2009 May; 296(5):C1086-97. PubMed ID: 19279227
[TBL] [Abstract][Full Text] [Related]
39. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation.
Sharom FJ; Lu P; Liu R; Yu X
Biochem J; 1998 Aug; 333 ( Pt 3)(Pt 3):621-30. PubMed ID: 9677321
[TBL] [Abstract][Full Text] [Related]
40. MDR1/P-glycoprotein in haematological neoplasms.
Marie JP; Zhou DC; Gurbuxani S; Legrand O; Zittoun R
Eur J Cancer; 1996 Jun; 32A(6):1034-8. PubMed ID: 8763345
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
